Vertex Signs an Exclusive License Agreement with Merck KGaA for its Two DNA-PK Inhibitor

 Vertex Signs an Exclusive License Agreement with Merck KGaA for its Two DNA-PK Inhibitor

Vertex Signs an Exclusive License Agreement with Merck KGaA for its Two DNA-PK Inhibitor

Shots:

  • Merck KGaA to receive upfront, milestones, and royalties on net sales. Vertex to get exclusive license rights for Merck’s two DNA-dependent protein kinase (DNA-PK) inhibitors, M9831 (formerly known as VX-984) and a preclinical candidate for six genetic disease indications to fields of gene-editing
  • Vertex will have an option to add indications to the above agreement and Merck will retain rights for its two DNA-PK candidates in all indication (EX- for Vertex) including oncology
  • M9831 (formerly known as VX-984) is a DNA-PK inhibitor, evaluated in P-I for solid tumors. In 2017, Merck in-licensed Vertex’s four candidates including its VX-984 DNA-PK Inhibitors for DNA damage and repair

Click here to read full press release/ article | Ref: Merck | Image: Twitter

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post